Clear Street raised the firm’s price target on Erasca (ERAS) to $20 from $11 and keeps a Buy rating on the shares. The company announced a clinical trial and supply agreement with Tango Therapeutics to evaluate ERAS-0015 in combination with Tango’s PRMT5 inhibitor, vopimetostat, and the firm views this as a capital-efficient initiative that increases ERAS-0015’s combination flexibility and brings an MTAPdel RASm approach, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Midday Fly By: Stocks tumble as oil prices climb again
- Erasca, Tango Therapeutics enter clinical collaboration, supply agreement
- Is the SPDR S&P Biotech ETF (XBI) a ‘Strong Buy’ Right Now?
- Erasca announces issuance of U.S. patent covering ERAS-4001
- Erasca extends cash runway after upsized public offering